Cancer BiologybioRxivPreprint
Targeting Aberrant FGFR Signaling with Infigratinib Enhances the Efficacy of BTK/PI3K Inhibitors and Bendamustine in Lymphoma Cells
Giulio Sartori, Alessandro Ghiringhelli, Eleonora Cannas…·Francesco Bertoni
This study shows that combining infigratinib with BTK/PI3K inhibitors or bendamustine improves efficacy in lymphoma cell models, reversing resistance and suggesting FGFR inhibition as a therapeutic strategy.
DOI 10.64898/2025.12.23.695986